CM
AVBP icon

Caption Management’s ArriVent BioPharma AVBP Stock Holding History

Caption Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,000
Closed -$424K – 2145
2025
Q3 		$424K Buy
+23,000
New +$452K ﹤0.01% 1336

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caption Management's AVBP Position: Q1 2026 in Review

Caption Management opened a new position in ArriVent BioPharma (AVBP) in Q1 2026: 15,967 shares worth $368K. The stake represents ﹤0.01% of the portfolio and ranks #1264 among its holdings. This is a return to the name: Caption Management previously reported a position in AVBP as recently as Q3 2025.

Caption Management first reported a position in AVBP in Q3 2025 and has held it in 2 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Caption Management held 15,967 shares of ArriVent BioPharma worth $368K as of Q1 2026.
  • ArriVent BioPharma was a new Caption Management position in Q1 2026.
  • ArriVent BioPharma made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1264 holding.
  • Caption Management first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 2 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.